Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Comparison of promoter hypermethylation pattern in salivary rinses collected with and without an exfoliating brush from patients with HNSCC.

Sun W, Zaboli D, Liu Y, Arnaoutakis D, Khan T, Wang H, Koch W, Khan Z, Califano JA.

PLoS One. 2012;7(3):e33642. doi: 10.1371/journal.pone.0033642. Epub 2012 Mar 16.

2.

Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer.

Sun W, Zaboli D, Wang H, Liu Y, Arnaoutakis D, Khan T, Khan Z, Koch WM, Califano JA.

Clin Cancer Res. 2012 Feb 15;18(4):1082-91. doi: 10.1158/1078-0432.CCR-11-2392. Epub 2012 Jan 6.

3.
4.

Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from head and neck squamous cell carcinoma patients.

Rettori MM, de Carvalho AC, Bomfim Longo AL, de Oliveira CZ, Kowalski LP, Carvalho AL, Vettore AL.

Carcinogenesis. 2013 Jan;34(1):20-7. doi: 10.1093/carcin/bgs311. Epub 2012 Oct 5.

5.

Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance.

Carvalho AL, Henrique R, Jeronimo C, Nayak CS, Reddy AN, Hoque MO, Chang S, Brait M, Jiang WW, Kim MM, Claybourne Q, Goldenberg D, Khan Z, Khan T, Westra WH, Sidransky D, Koch W, Califano JA.

Clin Cancer Res. 2011 Jul 15;17(14):4782-9. doi: 10.1158/1078-0432.CCR-11-0324. Epub 2011 May 31.

6.

Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.

Nayak CS, Carvalho AL, Jeronimo C, Henrique R, Kim MM, Hoque MO, Chang S, Jiang WW, Koch W, Westra W, Sidransky D, Califano J.

Laryngoscope. 2007 Aug;117(8):1376-80.

PMID:
17592394
7.
8.

Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma.

Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, Chang S, Brait M, Nayak CS, Jiang WW, Claybourne Q, Tokumaru Y, Lee J, Goldenberg D, Garrett-Mayer E, Goodman S, Moon CS, Koch W, Westra WH, Sidransky D, Califano JA.

Clin Cancer Res. 2008 Jan 1;14(1):97-107. doi: 10.1158/1078-0432.CCR-07-0722.

9.

Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma.

Krajnović M, Radojković M, Davidović R, Dimitrijević B, Krtolica K.

Med Oncol. 2013 Mar;30(1):441. doi: 10.1007/s12032-012-0441-3. Epub 2012 Dec 30.

PMID:
23275143
10.

TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors.

Rettori MM, de Carvalho AC, Longo AL, de Oliveira CZ, Kowalski LP, Carvalho AL, Vettore AL.

J Transl Med. 2013 Dec 20;11:316. doi: 10.1186/1479-5876-11-316.

11.

Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma.

Rastetter M, Schagdarsurengin U, Lahtz C, Fiedler E, Marsch WCh, Dammann R, Helmbold P.

Histol Histopathol. 2007 Sep;22(9):1005-15.

PMID:
17523078
12.

Validation of methylation markers for diagnosis of oral cavity cancer.

Arantes LM, de Carvalho AC, Melendez ME, Centrone CC, Góis-Filho JF, Toporcov TN, Caly DN, Tajara EH, Goloni-Bertollo EM, Carvalho AL; GENCAPO.

Eur J Cancer. 2015 Mar;51(5):632-41. doi: 10.1016/j.ejca.2015.01.060. Epub 2015 Feb 13.

PMID:
25686481
13.

DAPK promoter hypermethylation in tissues and body fluids of oral precancer patients.

Liu Y, Zhou ZT, He QB, Jiang WW.

Med Oncol. 2012 Jun;29(2):729-33. doi: 10.1007/s12032-011-9953-5. Epub 2011 Apr 24.

PMID:
21516484
14.

Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.

Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, Liu WJ.

Hum Pathol. 2009 Nov;40(11):1534-42. doi: 10.1016/j.humpath.2009.01.029. Epub 2009 Aug 19.

PMID:
19695681
15.

KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses.

Demokan S, Chang X, Chuang A, Mydlarz WK, Kaur J, Huang P, Khan Z, Khan T, Ostrow KL, Brait M, Hoque MO, Liegeois NJ, Sidransky D, Koch W, Califano JA.

Int J Cancer. 2010 Nov 15;127(10):2351-9. doi: 10.1002/ijc.25248.

16.

Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.

Nakamichi I, Tomita Y, Zhang B, Sugiyama H, Kanakura Y, Fukuhara S, Hino M, Kanamaru A, Ogawa H, Aozasa K.

Ann Hematol. 2007 Aug;86(8):557-64. Epub 2007 May 17.

PMID:
17508213
17.

Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients.

Yuregir OO, Yurtcu E, Kizilkilic E, Kocer NE, Ozdogu H, Sahin FI.

Int J Lab Hematol. 2010 Apr;32(2):142-9. doi: 10.1111/j.1751-553X.2009.01146.x. Epub 2009 Mar 2.

PMID:
19302404
18.

Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression.

Iliopoulos D, Oikonomou P, Messinis I, Tsezou A.

Oncol Rep. 2009 Jul;22(1):199-204.

PMID:
19513524
19.

Promoter methylation of cyclin A1 is associated with human papillomavirus 16 induced head and neck squamous cell carcinoma independently of p53 mutation.

Weiss D, Basel T, Sachse F, Braeuninger A, Rudack C.

Mol Carcinog. 2011 Sep;50(9):680-8. doi: 10.1002/mc.20798. Epub 2011 May 11.

PMID:
21563216
20.

Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients.

Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D.

Cancer Res. 2001 Feb 1;61(3):939-42.

Items per page

Supplemental Content

Write to the Help Desk